Stem Cell Sciences suspends trading, reviews options

The UK's Stem Cell Sciences, which has been commercializing stem cell technology, asked for a temporary suspension in the trading of its shares as it reviews a lineup of strategic options that include a possible sale of assets, refinancing and a merger. SCS says it's already engaged in a number of discussions along those lines.

Just last week Pfizer announced a five-year deal for SCS' research services. And a little more than a week ago it revealed a pair of deals for its technology. One company agreed to pay SCS £480k over six years for access to its technology and CHDI foundation inked a services agreement.

- see the release on the Pfizer deal
- read the report from SmallCapNews

Related Article:
Pfizer launches regenerative medicine unit